Poly cystic Ovary Syndrome. Polycystic Ovarian Syndrome
Conditions
Interventions
Intervention 1: All of the patients will be received 4 mg of pioglithazone twice a day for 5 days. Intervention 2: All of the patients will be received 4 mg of pioglithazone twice a day for 5 days aft
Treatment - Drugs
All of the patients will be received 4 mg of pioglithazone twice a day for 5 days.
All of the patients will be received 4 mg of pioglithazone twice a day for 5 days after that subjects will be received 50 mg of clomiphen citrate twice a day for 5 days in addition to pioglithazone wh
Sponsors
Hormozgan University of Medical Science
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with history of anovulatory cycles during the past two months in addition to one of the following conditions:Serum progestrone level less than 5 mg during the mid-luteal phase; Hirsutism; Positive response to medroxy-progesterone acetate withdrawal test; Serum testosterone level higher than 65 Ng/Dl Exclusion criteria; patients with confirmed diabetes mellitus or fasting blood glucose higher than 125 mg/dl; congenital adrenal hyperplasia which was confirmed by 17-alpha hydroxy progesterone level of 200 ng/dl or higher; patients with underlying disorders such as thyroid disease; hyperprolactinemia; congenital heart disease; hypertension; renal and liver dysfunction; patients who had received any hypoglycemic agent or inducing ovulation medications during 30days ago.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ovulation. Timepoint: one month after intervention. Method of measurement: vaginal bleeding. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pregnancy. Timepoint: 2 month after intervention. Method of measurement: beta human chorionic gonadotropine of serum. | — |
Countries
Iran (Islamic Republic of)
Outcome results
None listed